MCK241206P410000
- 0.00
- 0.000.00%
McKesson Newsroom
Investors in McKesson (NYSE:MCK) Have Seen Massive Returns of 356% Over the Past Five Years
This month's US stock hot stocks | Is the third wave of AI investment frenzy coming? Applovin soared 93.97% in the month, palantir surged 58.93%; AI electrical utilities demand surged + excellent performance, VST rose 23.66% this month
As of the close of the U.S. stock market on Wednesday, November 27, the three major U.S. indices continued to reach historical highs this month, with the dow jones industrial average rising 7.08%, marking the largest monthly increase of the year.
McKesson To Go Ex-Dividend On December 2nd, 2024 With 0.71 USD Dividend Per Share
November 28th (Eastern Time) - $McKesson(MCK.US)$ is trading ex-dividend on December 2nd, 2024.Shareholders of record on December 2nd, 2024 will receive 0.71 USD dividend per share on January 2nd, 202
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
Why McKesson (MCK) Is a Top Value Stock for the Long-Term
Biden Proposes Medicare, Medicaid Coverage of Obesity Drugs
Do Wall Street Analysts Like McKesson Stock?
McKesson Stock Gains 34.1% YTD: What's Driving the Rally?
McKesson Corporation (NYSE:MCK) Is Favoured by Institutional Owners Who Hold 89% of the Company
The US Oncology Network Launches Innovative Program to Foster Retention of New Oncology Nurses
Jefferies Maintains McKesson(MCK.US) With Buy Rating, Raises Target Price to $715
Jefferies Sticks to Its Buy Rating for McKesson (MCK)
High Alpha Stocks That Are Rated 'Overweight' – MS
Jefferies Raises Price Target on McKesson to $715 From $607
J.P. Morgan Maintains McKesson(MCK.US) With Buy Rating, Raises Target Price to $708
J.P. Morgan Sticks to Their Buy Rating for McKesson (MCK)
AZURITY PHARMACEUTICALS, INC ANNOUNCES FDA APPROVAL OF DANZITEN (Nilotinib) Tablets, THE FIRST AND ONLY NILOTINIB WITH NO MEALTIME RESTRICTIONS
McKesson's (NYSE:MCK) Conservative Accounting Might Explain Soft Earnings
InspiroGene by McKesson Partners With Vertex To Expand Distribution Of CASGEVY, The First FDA-Approved CRISPR Gene-Editing Therapy For Sickle Cell Disease And Β-Thalassemia
Investors Can Find Comfort In McKesson's (NYSE:MCK) Earnings Quality